Modelling prognostic factors in advanced pancreatic cancer

British Journal of Cancer

Volumn 99, Issue 6, 2008, Pages 883-893

  Stocken, D D ^a   Hassan, A B ^b   Altman, D G ^c   Billingham, L J ^a   Bramhall, S R ^d   Johnson, P J ^a   Freemantle, N ^a  

^a UNIVERSITY OF BIRMINGHAM   (United Kingdom)

^b UNIVERSITY OF OXFORD   (United Kingdom)

^c UNIVERSITY OF OXFORD   (United Kingdom)

^d QUEEN ELIZABETH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALKALINE PHOSPHATASE; ASPARTATE AMINOTRANSFERASE; CA 19-9 ANTIGEN; GEMCITABINE; LACTATE DEHYDROGENASE; MARIMASTAT;

ADULT; ADVANCED CANCER; AGED; ALKALINE PHOSPHATASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER SURVIVAL; CANCER THERAPY; FEMALE; HUMAN; LACTATE DEHYDROGENASE BLOOD LEVEL; LEUKOCYTE COUNT; MAJOR CLINICAL STUDY; MALE; METASTASIS; PANCREAS CANCER; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; STATISTICAL MODEL; UREA NITROGEN BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; CLINICAL TRIALS, PHASE III AS TOPIC; FEMALE; HUMANS; MALE; MIDDLE AGED; MODELS, STATISTICAL; PANCREATIC NEOPLASMS; PROGNOSIS; PROSPECTIVE STUDIES; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SURVIVAL RATE;

EID: 51449086005     PISSN: 00070920     EISSN: 15321827     Source Type: Journal    
DOI: 10.1038/sj.bjc.6604568     Document Type: Article

References (57)

1. Alexakis N, Halloran C, Raraty M, Ghaneh P, Sutton R, Neoptolemos JP (2004) Current standards of surgery for pancreatic cancer. Brit J Surg 91: 1410-1427
2. Altman DG, Lyman GH (1998) Methodological challenges in the evaluation of prognostic factors in breast cancer. Breast Cancer Res Treat 52: 289-303
3. Altman DG, Royston P (2006) The cost of dichotomising continuous variables. BMJ 332: 1080
4. Bachmann MO, Alderson D, Peters TJ, Bedford C, Edwards D, Wotton S, Harvey IM (2003) Influence of specialization on the management and outcome of patients with pancreatic cancer. Br J Surg 90(2): 171-177
5. Berlin JD, Catalano P, Thomas JP, Kugler JW, Haller DG, Bowen Benson A (2002) Phase III study of gemcitabine in combination with fluorouracil versus gemcitabine alone in patients with advanced pancreatic carcinoma: Eastern Cooperative Oncology Group Trials E2297. J Clin Oncol 20(15): 3270-3275
6. Birkmeyer JD, Warshaw AL, Finlayson SRG, Grove MR, Tosteson ANA (1999) Relationship between hospital volume and late survival after pancreatoduodenectomy. Surgery 126: 178-183
7. Bramhall SR, Allum WH, Jones AG, Allwood A, Cummins C, Neoptolemos JP (1995) Treatment and survival in 13 560 patients with pancreatic cancer, and incidence of the disease, in the West Midlands: an epidemiological study. Br J Surg 82(1): 111-115
8. Bramhall SR, Rosemurgy A, Brown PD, Bowry C, Buckels JAC (2001) Marimastat as first-line therapy for patients with unresectable pancreatic cancer: a randomised trial. J Clin Oncol 19: 3447-3455
9. Bramhall SR, Schulz J, Nemunaitis J, Brown PD, Baillet M, Buckels JAC (2002) A double-blind placebo-controlled, randomised study comparing gemcitabine and marimastat with gemcitabine and placebo as first line therapy in patients with advanced pancreatic cancer. Br J Cancer 87: 161-167
10. Collett D (1994) Modelling Survival Data in Medical Research. London: Chapman and Hall
11. Cubiella J, Castells A, Fondevila C, Sans M, Sabater L, Navarro S, Fernandez-Cruz L (1999) Prognostic factors in nonresectable pancreatic adenocarcinoma: a rationale to design therapeutic trials. Am J Gastroenterol 94(5): 1271-1278
12. Ducreux M, Rougier P, Pignon JP, Douillard JY, Seitz JF, Bugat R, Bossett JF, Merouche Y, Raoul JL, Ychou M, Adenis A, Berthault-Cvitkovic F, Luboinski M (2002) A randomised trial comparing 5-FU with 5-FU plus cisplatin in advanced pancreatic carcinoma. Ann Oncol 13: 1185-1191
13. Engelken FJF, Bettschart V, Rahman MQ, Parks RW, Garden OJ (2003) Prognostic factors in the palliation of pancreatic cancer. Eur J Surg Oncol 29(4): 368-373
14. Falconer JS, Fearon KCH, Ross JA, Elton R, Wigmore SJ, Garden OJ, Carter DC (1995) Acute-phase protein response and survival duration of patients with pancreatic cancer. Cancer 75(8): 2077-2082
15. Friedman GD, van den Eeden SK (1993) Risk factors for pancreatic cancer: an exploratory study. Int J Epidemiol 22(1): 30-37
16. Fujino Y, Suzuki Y, Ajiki T, Tanioka Y, Ku YS, Kuroda Y (2003) Predicting factors for survival of patients with unresectable pancreatic cancer: a management guideline. Hepatogastroenterol 50(49): 250-253
17. Gupta D, Lis CG, Dahlk SL, Vashi PG, Grutsch JF, Lammersfeld CA (2004) Bioelectrical impedance phase angle as a prognostic indicator in advanced pancreatic cancer. Br J Nutr 92(6): 957-962
18. Halm U, Schumann T, Schiefke I, Witzigmann H, Mossner J, Keim V (2000) Decrease of CA 19-9 during chemotherapy with gemcitabine predicts survival time in patients with advanced pancreatic cancer. Br J Cancer 82(5): 1013-1016
19. Harrell FE, Lee KL, Mark DB (1996) Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 15: 361-387
20. Ikeda W, Okada S, Tokuuye K, Ueno H, Okusaka T (2001) Prognostic factors in patients with locally advanced pancreatic carcinoma receiving chemoradiotherapy. Cancer 91(3): 490-495
21. Ishii H, Okada S, Nose H, Yoshimori M, Aoki K, Okusaka T (1996) Prognostic factors in patients with advanced pancreatic cancer treated with systemic chemotherapy. Pancreas 12(3): 267-271
22. Jemal A, Murray T, Samuels A, Ghafoor A, Ward E, Thun MJ (2003) Cancer statistics, 2003. CA Cancer J Clin 53: 5-26
23. Johnson CD, Puntis M, Davidson N, Todd S, Bryce R (2001) Randomised, dose-finding phase III study of lithium gamolenate in patients with advanced pancreatic adenocarcinoma. Br J Surg 88: 662-668
24. Karayiannakis AJ, Bolanaki H, Syrigos KN, Asimakopoulos B, Polychronidis A, Anagnostoulis S, Simopoulos C (2003) Serum vascular endothelial growth factor levels in pancreatic cancer patients correlate with advanced and metastatic disease and poor prognosis. Cancer Lett 194(1): 119-124
25. Kuhlmann KFD, de Castro SMM, Wesseling JG, ten Kate FJW, Offerhaus GJA, Busch ORC, van Gulik TM, Obertop H, Gouma DJ (2004) Surgical treatment of pancreatic adenocarcinoma: actual survival and prognostic factors in 343 patients. Eur J Cancer 40: 549-558
26. Lundin J, Roberts PJ, Kuusela P, Haglund C (1995) Prognostic significance of serum CA 242 in pancreatic cancer. A comparison with CA 19-9. Anticancer Res 15(5B): 2181-2186
27. Maisey N, Chau I, Cunningham D, Norman A, Seymour M, Hickish T, Iveson T, O'Brien M, Tebbutt N, Harrington A, Hill M (2002) Multicenter randomized phase III trial comparing protracted venous infusion (PVI) fluorouracil (5-FU) with PVI 5-FU plus mitomycin in inoperable pancreatic cancer. J Clin Oncol 20(14): 3130-3136
28. McShane LM, Altman DG, Sauerbrei W, Taube SE, Gion M, Clark GM (2005) Reporting recommendations for tumour marker prognostic studies (REMARK). Br J Cancer 93: 387-391
29. Meier-Hirmer C, Ortseifen C, Sauerbrei W (2003) Multivariable Fractional Polynomials in SAS. SAS Institute, SAS Circle: Cary. NC, USA
30. Micke O, Bruns F, Kurowski R, Horst E, deVries AF, Hausler JW, Willich N, Schafer U (2003) Predictive value of carbohydrate antigen 19-9 in pancreatic cancer treated with radiochemotherapy. Int J Radiat Oncol Biol Phys 57(1): 90-97
31. Neoptolemos JP, Russell RCG, Bramhall S, Theis B (1997) Low mortality following resection for pancreatic and periampullary tumours in 1026 patients: UK survey of specialist pancreatic units. Br J Surg 84: 1370-1376
32. Ni XG, Bai XF, Mao YL, Shao YF, Wu JX, Shan Y, Wang CF, Wang J, Tian YT, Liu Q, Xu DK, Zhao P (2005) The clinical value of serum CEA, CA19-9 and CA242 in the diagnosis and prognosis of pancreatic cancer. Eur J Surg Oncol 31: 164-169
33. Ohigashi H, Ishikawa O, Yokayama S, Sasaki Y, Yamada T, Imaoka S, Nakaizumi A, Uehara H (2003) Intra-arterial infusion chemotherapy with angiotensin-II for locally advanced and nonresectable pancreatic adenocarcinoma: further evaluation and prognostic implications. Ann Surg Oncol 10(8): 927-934
34. Paillaud E, Bories PN, Aita SL, Scherman E, Jeanfaivre V, Lejonc JL, Campillo B (2003) Prognostic value of dietary intake and inflammation on survival in patients with advanced cancer: relationship with performance status, pain, and digestive disorders. Nutr Cancer 45(1): 30-35
35. Parkin DM, Bray FI, Devesa SS (2001) Cancer burden in the year 2000. The global picture. Eur J Cancer 37(Suppl 8): S4-S66
36. Ridwelski K, Meyer F, Ebert M, Malfertheiner P, Lippert H (2001) Prognostic parameters determining survival in pancreatic carcinoma and, in particular, after palliative treatment. Digest Dis 19(1): 85-92
37. Rothenberg ML, Moore ML, Cripps MC, Anderson JS, Portenoy RK, Burris HA, Green MR, Tarassoff PG, Brown TD, Casper ES, Storniolo AM, Von Hoff DD (1996) A phase II trial of gemcitabine in patients with 5-FU-refractory pancreas cancer. Ann Oncol 7: 347-353
38. Royston P, Altman DG (1994) Regression using fractional polynomials of continuous covariates: parsimonious parametric modelling. Appl Stat 43(3): 429-467
39. Royston P, Altman DG, Sauerbrei W (2006a) Dichotomising continuous predictors in multiple regression: a bad idea. Stat Med 25: 127-141
40. Royston P, Reitz M, Atzpodien J (2006b) An approach to estimating prognosis using fractional polynomials in metastatic renal carcinoma. Br J Cancer 94: 1785-1788
41. Rubin DB (1987) Multiple Imputation for Nonresponse in Surveys. Wiley: New York
42. Saad ED, Machado MC, Wajsbrot D, Abramoff R, Hoff PM, Tabacof J, Katz A, Simon SD, Gansl RC (2002) Pretreatment CA 19-9 level as a prognostic factor in patients with advanced pancreatic cancer treated with gemcitabine. Int J Gastrointest Cancer 32(1): 35-41
43. Sauerbrei W, Royston P, Bojar H, Schmoor C, Schumacher M (1999) Modelling the effects of standard prognostic factors in node-positive breast cancer. Br J Cancer 79: 1752-1760
44. Schafer JL (1997) Analysis of Incomplete Multivaraite Data. Chapman and Hall: London
45. Sener SF, Fremgen A, Menck HR, Winchester DP (1999) Pancreatic cancer: a report of treatment and survival trends for 100 313 patients diagnosed from 1985-1995, using the National Cancer Database. J Am Coll Surg 189: 1-7
46. Shibamoto Y, Manabe T, Ohshio G, Sasai K, Nishimura Y, Imamura M, Takahashi M, Abe M (1996) High-dose intraoperative radiotherapy for unresectable pancreatic cancer. Int J Radiat Oncol Biol Phys 34(1): 57-63
47. Stemmler J, Stieber P, Szymala AM, Schalhorn A, Schermuly MM, Wilkowski R, Helmberger T, Lamerz R, Stoffregen C, Niebler K, Garbrecht M, Heinemann V (2003) Are serial CA 19-9 kinetics helpful in predicting survival in patients with advanced or metastatic pancreatic cancer treated with gemcitabine and cisplatin? Onkologie 26(5): 462-467
48. Storniolo AM, Enas NH, Brown CA, Voi M, Rothenberg ML, Schilsky R (1999) An investigational new drug treatment program for patients with gemcitabine. Cancer 85(6): 1261-1268
49. Talar-Wojnarowska R, Gasiorowska A, Strzelczyk J, Janiak A, Malecka-Panas E (2003) Prognostic factors in the operative and palliative treatment of pancreatic cancer. Neoplasma 50(5): 383-387
50. Tas F, Aykan F, Alici S, Kaytan E, Aydiner A, Topuz E (2001) Prognostic factors in pancreatic carcinoma - serum LDH levels predict survival in metastatic disease. Am J Clin Oncol 24(6): 547-550
51. Terwee CB, Van Dijkum EJMN, Gouma DJ, Bakkevold KE, Klinkenbijl JHG, Wade TP, van Wagensveld BA, Wong A, van der Meulen JHP (2000) Pooling of prognostic studies in cancer of the pancreatic head and periampullary region: the triple-P study. Eur J Surg 166(9): 706-712
52. Trigui B, Barrier A, Flahault A, Huguier M (2000) Prognostic factors in advanced pancreatic carcinoma. Multivariate analysis and predictive score of survival. Ann Chir 125(7): 625-630
53. Tsuruta K, Okamoto A, Egawa N, Kamisawa T, Karasawa K, Takahashi T (2001) Survival benefits of adjuvant chemotherapy with oral doxifluridine (5-DFUR) following radiotherapy in patients with unresectable pancreatic cancer. J Surg Oncol 78: 202-207
54. Ueno H, Okada S, Okusaka T, Ikeda M (2000) Prognostic factors in patients with metastatic pancreatic adenocarcinoma receiving systemic chemotherapy. Onkologie 59(4): 296-301
55. Watanabe I, Sasaki S, Konishi M, Nakagohri T, Inoue K, Oda T, Kinoshita T (2004) Onset symptoms and tumor locations as prognostic factors of pancreatic cancer. Pancreas 28(2): 160-165
56. Yasue M, Sakamoto J, Teramukai S, Morimoto T, Yasui K, Kuno N, Kurimoto K, Ohashi Y (1994) Prognostic values of preoperative and postoperative CEA and CA19-9 levels in pancreatic cancer. Pancreas 9(6): 735-740
57. Ziske C, Schlie C, Gorschluter M, Glasmacher A, Mey U, Strehl J, Sauerbruch T, Schmidt-Wolf IGH (2003) Prognostic value of CA 19-9 levels in patients with inoperable adenocarcinoma of the pancreas treated with gemcitabine. Br J Cancer 89(8): 1413-1417